$10995 | Single User
$21990 | Site License
$32985 | Enterprise License

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Published by Global Data: 08 Aug 2016 | 27679 | In Stock

Introduction

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Summary

Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable angina (UA), myocardial infarction (MI) and/or death due to myocardial ischemia. In general, these ACS events can be viewed as the culmination of coronary artery disease (CAD), the asymptomatic build-up of atherosclerotic plaque on the walls of the coronary arteries. The triggering of an ACS event stemming from UA or MI initiates the acute phase treatment setting where therapeutic interventions are utilized to reverse and prevent the physiochemical processes that lead to coronary stenosis. Whereas, the chronic phase treatment setting involves secondary preventative measures that are used to avoid recurrent ACS events from occurring.

Highlights

Key Questions Answered

- The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?

- The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

- We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases , as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?

Key Findings

- The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.

- The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.

- The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.

- The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.

Scope

- Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global ACS therapeutics market from 2015-2025.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • 1 Table of Contents

    1 Table of Contents 10

    1.1 List of Tables 16

    1.2 List of Figures 22

    2 Introduction 24

    2.1 Catalyst 24

    2.2 Related Reports 25

    2.3 Upcoming Related Reports 25

    3 Disease Overview 26

    3.1 Etiology and Pathophysiology 27

    3.1.1 Etiology 27

    3.1.2 Pathophysiology 31

    3.2 Classification or Staging Systems 33

    3.3 Symptoms 34

    3.4 Prognosis 35

    3.5 Quality of Life 36

    4 Epidemiology 37

    4.1 Disease Background 37

    4.2 Risk Factors and Comorbidities 38

    4.3 Global Trends 41

    4.3.1 ACS Diagnosed Prevalence 41

    4.3.2 STEMI and NSTEMI Trends 44

    4.3.3 ACS Hospitalizations 45

    4.4 Forecast Methodology 47

    4.4.1 Sources Used 50

    4.4.2 Forecast Assumptions and Methods 57

    4.4.3 Sources Not Used 70

    4.5 Epidemiological Forecast for ACS (2015-2025) 71

    4.5.1 Diagnosed Prevalent Cases of ACS 71

    4.5.2 Age-Specific Diagnosed Prevalent Cases of ACS 73

    4.5.3 Sex-Specific Diagnosed Prevalent Cases of ACS 75

    4.5.4 Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA 77

    4.5.5 Age-Standardized Diagnosed Prevalence of ACS 79

    4.5.6 ACS Hospitalizations 80

    4.5.7 Sex-Specific ACS Hospitalizations 82

    4.5.8 ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA 84

    4.6 Discussion 86

    4.6.1 Epidemiological Forecast Insight 86

    4.6.2 Limitations of the Analysis 87

    4.6.3 Strengths of the Analysis 88

    5 Disease Management 90

    5.1 Diagnosis and Treatment Overview 90

    5.1.1 Diagnosis 90

    5.1.2 Treatment Guidelines and Leading Prescribed Drugs 91

    5.1.3 Clinical Practice 96

    5.2 US 99

    5.3 5EU 102

    5.4 Japan 106

    6 Competitive Assessment 109

    6.1 Overview 109

    6.2 Product Profiles - Acute Coronary Syndrome 112

    6.2.1 Antihypertensives 112

    6.2.2 Anticoagulants 130

    6.2.3 Fibrinolytics 150

    6.2.4 Antidyslipidemics 155

    6.2.5 Antiplatelets 176

    7 Unmet Need and Opportunity 209

    7.1 Overview 209

    7.2 Management of ACS in Elderly Patients 210

    7.2.1 Unmet Need 210

    7.2.2 Gap Analysis 211

    7.2.3 Opportunity 212

    7.3 Blood Thinning Agent with Reduced Bleeding 213

    7.3.1 Unmet Need 213

    7.3.2 Gap Analysis 214

    7.3.3 Opportunity 214

    7.4 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 215

    7.4.1 Unmet Need 215

    7.4.2 Gap Analysis 216

    7.4.3 Opportunity 217

    7.5 Achieving Guideline-Recommended Levels of LDL-C 217

    7.5.1 Unmet need 217

    7.5.2 Gap Analysis 218

    7.5.3 Opportunity 219

    7.6 Optimal Treatment of ACS Patients with Hyperglycemia 220

    7.6.1 Unmet Need 220

    7.6.2 Gap Analysis 220

    7.6.3 Opportunity 221

    8 Pipeline Assessment 222

    8.1 Overview 222

    8.2 Promising Drugs in Clinical Development 224

    8.2.1 Bococizumab 225

    8.2.2 Anacetrapib 231

    8.2.3 CSL-112 238

    8.2.4 CER-001 246

    8.2.5 LY3015014 253

    8.2.6 AMG-899 257

    8.2.7 ETC-1002 262

    9 Current and Future Players 268

    9.1 Overview 268

    9.2 Trends in Corporate Strategy 273

    9.3 Company Profiles 275

    9.3.1 Amgen 275

    9.3.2 AstraZeneca 277

    9.3.3 Bristol-Myers Squibb 279

    9.3.4 Cerenis Therapeutics 281

    9.3.5 CSL Limited 282

    9.3.6 Daiichi Sankyo 284

    9.3.7 Eli Lilly 286

    9.3.8 Esperion Therapeutics 287

    9.3.9 GlaxoSmithKline 288

    9.3.10 Janssen 290

    9.3.11 The Medicines Company 291

    9.3.12 Merck & Co. 294

    9.3.13 Pfizer 296

    9.3.14 Sanofi 298

    10 Market Outlook 301

    10.1 Global Market 301

    10.1.1 Forecast 301

    10.1.2 Drivers and Barriers - Global Issues 308

    10.2 United States 313

    10.2.1 Forecast 313

    10.2.2 Key Events 318

    10.2.3 Drivers and Barriers 318

    10.3 France 320

    10.3.1 Forecast 320

    10.3.2 Key Events 325

    10.3.3 Drivers and Barriers 325

    10.4 Germany 326

    10.4.1 Forecast 326

    10.4.2 Key Events 331

    10.4.3 Drivers and Barriers 332

    10.5 Italy 333

    10.5.1 Forecast 333

    10.5.2 Key Events 338

    10.5.3 Drivers and Barriers 339

    10.6 Spain 340

    10.6.1 Forecast 340

    10.6.2 Key Events 344

    10.6.3 Drivers and Barriers 344

    10.7 United Kingdom 345

    10.7.1 Forecast 345

    10.7.2 Key Events 350

    10.7.3 Drivers and Barriers 350

    10.8 Japan 352

    10.8.1 Forecast 352

    10.8.2 Key Events 356

    10.8.3 Drivers and Barriers 356

    11 Appendix 359

    11.1 Bibliography 359

    11.2 Abbreviations 389

    11.3 Methodology 396

    11.4 Forecasting Methodology 396

    11.4.1 Diagnosed Acute Coronary Syndrome Patients 396

    11.4.2 Percent Drug-Treated Patients 397

    11.4.3 Drugs Included in Each Therapeutic Class 397

    11.4.4 Launch and Patent Expiry Dates 398

    11.4.5 General Pricing Assumptions 399

    11.4.6 Individual Drug Assumptions 400

    11.4.7 Generic Erosion 408

    11.4.8 Pricing of Pipeline Agents 409

    11.5 Physicians and Specialists Included in this Study 410

    11.6 About the Authors 413

    11.6.1 Analyst 413

    11.6.2 Therapy Area Director 413

    11.6.3 Epidemiologist 414

    11.6.4 Global Director of Therapy and Epidemiology 414

    11.7 About GlobalData 415

    11.8 Disclaimer 415

List Of Tables
in PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

1.1 List of Tables

Table 1: Marketed Antiplatelet Agents that Inhibit Platelet Activation 29

Table 2: Marketed Anticoagulants that Inhibit the Coagulatory Cascade 29

Table 3: Antidyslipidemic agents 31

Table 4: Classifications of ACS 33

Table 5: Universal Classification of MI 34

Table 6: Symptoms of Acute Coronary Syndrome 35

Table 7: Risk Factors and Comorbidities for ACS 40

Table 8: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants 44

Table 9: 7MM, Sources of Diagnosed Prevalence Data for MI 51

Table 10: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI 52

Table 11: 7MM, Data Sources of ACS Hospitalizations 54

Table 12: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations 56

Table 13: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025 72

Table 14: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015 74

Table 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N (Row %), 2015 76

Table 16: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ≥25 Years, N (Row %), 2015 78

Table 17: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025 81

Table 18: 7MM, Sex-Specific ACS Hospitalizations, Ages ≥25 Years, N (Row %), 2015 83

Table 19: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ≥25 Years, Both Sexes, N, 2015 85

Table 20: Most-Prescribed Drugs for ACS by Class in the Global Markets, 2015 92

Table 21: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 94

Table 22: Country Profile for ACS - US 101

Table 23: Country Profile for ACS - 5EU 104

Table 24: Country Profile for ACS - Japan 107

Table 25: Leading Treatments for ACS, 2015 110

Table 26: Commonly Used Beta Blockers 113

Table 27: Product Profile - Beta Blockers 114

Table 28: Beta Blockers SWOT Analysis, 2015 116

Table 29: Global ACS Sales Forecasts [$m] for Beta Blockers, 2015-2025 117

Table 30: Commonly Used ACE Inhibitors 118

Table 31: Product Profile - ACE Inhibitors 119

Table 32: ACE InhibitorSWOT Analysis, 2015 121

Table 33 Global ACS Sales Forecasts [$m] for ACE inhibitors, 2015-2025 122

Table 34: Commonly Used ARBs 123

Table 35: Product Profile - Angiotensin Receptor Blockers (ARBs) 123

Table 36: ARB SWOT Analysis, 2015 125

Table 37: Global ACS Sales Forecasts [$m] for ARBs, 2015-2025 126

Table 38: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs) 127

Table 39: MRA SWOT Analysis, 2016 129

Table 40: Global ACS Sales Forecasts [$m] for MRAs, 2015-2025 130

Table 41: Product Profile - Warfarin 132

Table 42: Warfarin SWOT Analysis, 2015 134

Table 43: Global ACS Sales Forecasts [$m] for Warfarin, 2015-2025 135

Table 44: Product Profile - Angiomax 136

Table 45: AngiomaxSWOT Analysis, 2015 138

Table 46: Global ACS Sales Forecasts [$m] for Angiomax, 2015-2025 139

Table 47: Product Profile - Fondaparinux 141

Table 48: Arixtra SWOT Analysis, 2015 143

Table 49: Global ACS Sales Forecasts ($M) for Fondaparinux, 2015-2025 144

Table 50: Product Profile - Xarelto (rivaroxaban) 147

Table 51: Xarelto SWOT Analysis, 2015 149

Table 52: Global ACS Sales Forecast ($M) for Xarelto, 2015-2025 150

Table 53: Commonly Used tPAs 152

Table 54: Product Profile - Tissue Plasminogen Activator (tPA) 152

Table 55: FibrinolyticsSWOT Analysis, 2015 154

Table 56: Global ACS Sales Forecast ($M) for Fibrinolytics, 2015-2025 155

Table 57: Product Profile - Repatha (Evolocumab) 158

Table 58: Product Profile - Praluent (Alirocumab) 159

Table 59: PCSK9 inhibitors SWOT Analysis, 2015 161

Table 60: Global ACS Sales Forecasts [$m] for Repatha, 2015-2025 162

Table 61: Global ACS Sales Forecasts [$m] for Praluent, 2015-2025 163

Table 62: Product Profile - Atorvastatin 166

Table 63: Product Profile - Simvastatin 167

Table 64: Lipitor (Atorvastatin) SWOT Analysis, 2015 170

Table 65: Zocor (Simvastatin) SWOT Analysis, 2015 171

Table 66: Global ACS Sales Forecasts [$m] for Generic Statins, 2015-2025 172

Table 67: Product Profile - Crestor (Rosuvastatin) 173

Table 68: Crestor (Rosuvastatin) SWOT Analysis, 2015 175

Table 69: Global ACS Sales Forecasts [$m] for Crestor, 2015-2025 176

Table 70: Product Profile - Clopidogrel 178

Table 71: Clopidogrel SWOT Analysis, 2015 180

Table 72: Global ACS Acute Phase Sales Forecast ($M) for Clopidogrel, 2015-2025 181

Table 73: Global ACS Chronic Phase Sales Forecasts ($M) for Clopidogrel, 2015-2025 182

Table 74: Product Profile - Brilinta (ticagrelor) 184

Table 75: Brilinta (ticagrelor) SWOT Analysis, 2015 186

Table 76: Global Acute Phase ACS Sales Forecast ($M) for Brilinta, 2015-2025 187

Table 77: Global ACS Chronic Phase Sales Forecast ($M) for Brilinta, 2015-2025 188

Table 78: Product Profile - Effient (Prasugrel) 190

Table 79: Effient (Prasugrel) SWOT Analysis, 2015 192

Table 80: Global Acute Phase ACS Sales Forecast ($M) for Effient, 2015-2025 193

Table 81: Global ACS Chronic Phase Sales Forecast ($M) for Effient, 2015-2025 193

Table 82: Product Profile - Integrilin (Eptifibatide) 195

Table 83: Integrilin (Eptifibatide) SWOT Analysis, 2015 197

Table 84: Global ACS Sales Forecast ($M) for Integrilin, 2015-2025 198

Table 85: Product Profile - Cangrelor 200

Table 86: Kengreal (cangrelor) SWOT Analysis, 2015 202

Table 87: Global ACS Sales Forecasts ($M) for Kengreal, 2015-2025 203

Table 88: Product Profile - Zontivity (Vorapaxar) 205

Table 89: Vorapaxar SWOT Analysis, 2015 207

Table 90: Global ACS Sales Forecast ($M) for Zontivity, 2015-2025 208

Table 91: Unmet Need and Opportunity in ACS 210

Table 92: Comparison of Therapeutic Classes in Development for ACS, 2015 224

Table 93: Comparison of Therapeutic Classes in Pipeline for ACS, 2016 225

Table 94: Product Profile - Bococizumab (PF-04950615) 227

Table 95: Bococizumab (PF-04950615) SWOT Analysis, 2015 230

Table 96: Global ACS Sales Forecasts [$m] for Bococizumab, 2015-2025 231

Table 97: Product Profile - Anacetrapib 234

Table 98: Anacetrapib SWOT Analysis, 2015 237

Table 99: Global ACS Sales Forecasts [$m] for Anacetrapib, 2015-2025 238

Table 100: Product Profile - CSL-112 241

Table 101: CSL-112 SWOT Analysis, 2015 244

Table 102: Global ACS Sales Forecasts [$m] for CSL-112, 2015-2025 245

Table 103: Product Profile - CER-001 248

Table 104: CER-001 SWOT Analysis, 2015 251

Table 105: Global ACS Sales Forecasts [$m] for CER-001, 2015-2025 252

Table 106: Product Profile - LY3015014 254

Table 107: LY3015014 SWOT Analysis, 2015 256

Table 108 Global ACS Sales Forecasts [$m] for LY3015014 , 2015-2025 257

Table 109: Product Profile - AMG-899 259

Table 110: AMG-899 SWOT Analysis, 2015 261

Table 111: Global ACS Sales Forecasts [$m] for AMG-899, 2015-2025 262

Table 112: Product Profile - ETC-1002 264

Table 113: ETC-1002 SWOT Analysis, 2016 266

Table 114: Global ACS Sales Forecasts [$m] for ETC-1002, 2015-2025 267

Table 115: Key Companies in the ACS Market, 2016 272

Table 116: Amgen’s ACS Portfolio Assessment, 2016 276

Table 117: AstraZeneca’s ACS Portfolio Assessment, 2015 279

Table 118: BMS’s ACS Portfolio Assessment, 2015 281

Table 119: Cerenis’ ACS Portfolio Assessment, 2015 282

Table 120: CSL Limited’s ACS Portfolio Assessment, 2015 283

Table 121: Daiichi Sankyo’s ACS Portfolio Assessment, 2015 285

Table 122: Eli Lilly’s ACS Portfolio Assessment, 2015 287

Table 123: Esperion’s ACS Portfolio Assessment, 2016 288

Table 124: GlaxoSmithKline’s Acute Coronary Syndrome Portfolio Assessment, 2015 290

Table 125: Janssen’s ACS Portfolio Assessment, 2015 291

Table 126: The Medicines Company’s Acute Coronary Syndrome Portfolio Assessment, 2015 294

Table 127: Merck’s ACS Portfolio Assessment, 2015 296

Table 128: Pfizer’s ACS Portfolio Assessment, 2015 298

Table 129: Sanofi’s ACS Portfolio Assessment, 2015 300

Table 130: Global Sales Forecasts [$m] for Acute Coronary Syndrome, 2015-2025 304

Table 131: ACS Global market - Drivers and Barriers, 2015-2025 308

Table 132: Sales Forecasts [$m] for Acute Coronary Syndrome in the US, 2015-2025 315

Table 133: Key Events Impacting Sales for ACS in the US, 2015-2025 318

Table 134: US ACS Market - Drivers and Barriers, 2015-2025 318

Table 135: Sales Forecasts [$m] for Acute Coronary Syndrome in France, 2015-2025 322

Table 136: Key Events Impacting Sales for ACS in France, 2015-2025 325

Table 137: France ACS market - Drivers and Barriers, 2015-2025 325

Table 138: Sales Forecasts [$m] for Acute Coronary Syndrome in Germany, 2015-2025 328

Table 139: Key Events Impacting Sales for ACS in Germany, 2015-2025 331

Table 140: Germany ACS market - Drivers and Barriers, 2015-2025 332

Table 141: Sales Forecasts [$m] for Acute Coronary Syndrome in Italy, 2015-2025 335

Table 142: Key Events Impacting Sales for ACS in Italy, 2015-2025 338

Table 143: Italy ACS market - Drivers and Barriers, 2015-2025 339

Table 144: Sales Forecasts [$m] for Acute Coronary Syndrome in Spain, 2015-2025 341

Table 145: Key Events Impacting Sales for ACS in Spain, 2015-2025 344

Table 146: Spain ACS Market - Drivers and Barriers, 2015-2025 344

Table 147: Sales Forecasts [$m] for Acute Coronary Syndrome in the UK, 2015-2025 347

Table 148: Key Events Impacting Sales for ACS in the UK, 2015-2025 350

Table 149: UK ACS market - Drivers and Barriers, 2015-2025 350

Table 150: Sales Forecasts [$m] for Acute Coronary Syndrome in Japan, 2015-2025 353

Table 151: Key Events Impacting Sales for ACS in Japan, 2015-2025 356

Table 152: Japan ACS Market - Drivers and Barriers, 2015-2025 356

Table 153: Key ACS Launch Dates 398

Table 154: Key Patent Expiries 398

Table 155: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 412

List Of Figures, Charts and Diagrams
in PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData’s ACS Report and Forecast 27

Figure 2: Progression of CAD, Atherosclerotic Plaque Rupture, Thrombosis, and ACS 28

Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 30

Figure 4: Electrocardiography in the Diagnosis of ACS 32

Figure 5: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008 42

Figure 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%) 44

Figure 7: Case Segmentation Map 50

Figure 8: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025 73

Figure 9; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015 75

Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N, 2015 77

Figure 11: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ≥25 Years, N, 2015 79

Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ≥25 Years, 2015 80

Figure 13: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025 82

Figure 14: 7MM, Sex-Specific ACS, Ages ≥25 Years, N, 2015 84

Figure 15: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ≥25 Years, Both Sexes, N, 2015 86

Figure 16: Company Portfolio Gap Analysis in ACS, 2015-2025 271

Figure 17: Global Sales for ACS by Region, 2015-2025 306

Figure 18: Global Sales for ACS by Class, 2015-2025 307

Figure 19 Global Sales for PCSK9 inhibitors for ACS, 2015-2025 308

Figure 20: Sales for ACS in the US by Drug Class, 2015-2025 317

Figure 21: Sales for ACS in France by Drug Class, 2015-2025 324

Figure 22: Sales for ACS in Germany by Drug Class, 2015-2025 330

Figure 23: Sales for ACS in Italy by Drug Class, 2015-2025 337

Figure 24: Sales for ACS in Spain by Drug Class, 2015-2025 343

Figure 25: Sales for ACS in the UK by Drug Class, 2015-2025 349

Figure 26: Sales for ACS in Japan by Drug Class, 2015-2025 355

Additional Details

Publisher

Global Data

Publisher Information

Reference

27679 | GDHC131PIDR

Number of Pages

416

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $10,995 More Info
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $10,995 More Info
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $10,995 More Info
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $10,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data